An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 [motesanib] Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer.

Trial Profile

An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 [motesanib] Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Motesanib (Primary) ; Cisplatin; Gemcitabine; Panitumumab
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 19 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and efficacy to safety only as reported by ClinicalTrials.gov record.
    • 24 Mar 2009 Primary outcome amended as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Planned end date (Feb 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top